research Effectiveness and safety of baricitinib in severe alopecia areata: 48-week results
Baricitinib effectively promotes hair regrowth and improves well-being in severe alopecia areata patients.
Search
for
Sort by
Research
810-840 / 1000+ resultsresearch Molecular crosstalk between lncRNA H19, miR-29a, and JAK2/STAT3 signaling in alopecia areata: a preliminary study
research A new way to restore tumour suppressor function
New treatments may restore cancer-blocking proteins, slow prostate cancer, identify drug targets, and potentially regrow hair.
research Successful treatment of alopecia universalis with abrocitinib: a case report
Abrocitinib may effectively treat stubborn alopecia universalis.
research Interleukin 6 and STAT3 regulate p63 isoform expression in keratinocytes during regeneration
The conclusion is that the IL-6/STAT3 activation affects p63 expression in healing wounds, which may help in hair follicle regeneration.
research Systemic Tofacitinib in Alopecia Areata: A Single Center Retrospective Descriptive Cohort Study
Tofacitinib effectively regrows hair in alopecia areata patients, especially in younger individuals, with manageable side effects.
research Targeted Disruption of Stat3 Reveals a Major Role for Follicular Stem Cells in Skin Tumor Initiation
Disrupting Stat3 in hair follicle stem cells greatly reduces skin tumor formation.
research Comparative efficacy and safety of systemic steroids, oral JAK inhibitors and Contact Immunotherapy in the Treatment of severe alopecia areata: a systematic review and network meta-analysis
Oral ritlecitinib and baricitinib are promising treatments for severe alopecia areata due to their balance of effectiveness and safety.
research Rapidly progressive alopecia areata totalis in a COVID‐19 patient, unresponsive to tofacitinib
A COVID-19 patient with severe hair loss did not improve with hair loss medication after stopping and restarting it due to the infection.
research Effectiveness and safety of baricitinib in patients with moderate‐to‐severe refractory alopecia areata in real world: An open‐label, single‐center study
Baricitinib effectively and safely improves hair growth in patients with severe alopecia areata.
research Skin toxicity caused by EGFR antagonists—An autoinflammatory condition triggered by deregulated IL‐1 signaling?
Blocking EGFR can cause skin inflammation by disrupting IL-1 signaling.
research Alopecia areata mit gutem Ansprechen auf Tofacitinib
Tofacitinib helped regrow hair in a woman with alopecia areata.
research Baricitinib for the treatment of severe alopecia areata: results from a 52-week multicenter retrospective real-world study
Baricitinib is effective and safe for treating severe alopecia areata, promoting significant hair regrowth.
research EX VIVO DRUG SENSITIVITY EVALUATION OF A RARE ZMYM2::FGFR1+ LEUKEMIA PATIENT
Pemigatinib may be effective for treating ZMYM2::FGFR1 fusion-positive leukemia.
research Cytokine-targeted treatment in alopecia areata - new possibilities?
New cytokine-targeted therapies show promise for treating alopecia areata.
research Alopecia areata treatment with baricitinib: different relapse phenotypes
Baricitinib can lead to hair regrowth in alopecia areata but may also cause relapses.
research Comparative Efficacy and Safety of Baricitinib Against Traditional Therapies in Severe Alopecia Areata: A Retrospective Cohort Study
Baricitinib is effective for severe alopecia areata but has some side effects.
research Efficacy and safety of baricitinib in patients with alopecia areata: evidence to date
Baricitinib is a promising treatment for alopecia areata.
research Safety of Tyrosine Kinase Inhibitors in Patients With Differentiated Thyroid Cancer: Real-World Use of Lenvatinib and Sorafenib in Korea
Lenvatinib and sorafenib are generally safe but need dose adjustments due to side effects.
research Switching between tofacitinib and baricitinib in alopecia areata: A review of clinical response
Switching between the medications tofacitinib and baricitinib can be effective for treating hair loss in alopecia areata.
research Demethylation of ITGAV accelerates osteogenic differentiation in a blast-induced heterotopic ossification in vitro cell culture model
Removing a methyl group from the ITGAV gene speeds up bone formation in a specific type of bone disease model.
research Pharmacological Mobilization of Endogenous Stem Cells Significantly Promotes Skin Regeneration after Full-Thickness Excision: The Synergistic Activity of AMD3100 and Tacrolimus
Using the drugs AMD3100 and Tacrolimus together greatly improves skin healing and hair growth after a deep skin cut by increasing stem cells in the wound.
research 557 Short-term Rho-associated kinase inhibitor treatment accelerates primary keratinocyte growth without affecting the characteristics of the stem cell population
Short-term treatment with ROCKi increases skin cell growth without changing stem cell features.
research Oral Combination Treatment of Gefitinib (IressaTM) and Sasam-Kyeongokgo: Synergistic Effects on the NCI-H520 Tumor Cell Line
Gefitinib and Sasam-Kyeongokgo together significantly reduce cancer growth and improve immune response in mice.
research Supplementary file 1_Evaluation of the efficacy and treatment-emergent adverse events of deuruxolitinib for moderate to severe alopecia areata: a dose-ranging meta-analysis of 1,372 randomized patients.docx
Deuruxolitinib effectively treats alopecia areata but may cause manageable side effects.
research Diffuse plate-like sheets of desquamation
The rash resolved after stopping ponatinib.
research The role of oclacitinib in the management of ischaemic dermatopathy in four dogs
Oclacitinib effectively treated a skin condition in dogs that didn't respond to other immunosuppressants.
research 294 Extensive alopecia areata is reversed by IL-12/23p40 cytokine antagonism
Blocking certain proteins can significantly regrow hair in severe alopecia areata.
research Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2)
Baricitinib improved severe hair loss in adults over 52 weeks and was safe to use.
research The Efficacy of Baricitinib as a Treatment Option for Alopecia, In Terms of Promoting Hair Regrowth and Improving Patient Reported Outcomes
Baricitinib effectively promotes hair regrowth in severe alopecia with minimal side effects.